Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec 1;102(12):4343-4410.
doi: 10.1210/jc.2017-01922.

Diabetic Microvascular Disease: An Endocrine Society Scientific Statement

Eugene J Barrett  1 , Zhenqi Liu  1 , Mogher Khamaisi  2 , George L King  2 , Ronald Klein  3 , Barbara E K Klein  3 , Timothy M Hughes  4 , Suzanne Craft  4 , Barry I Freedman  5 , Donald W Bowden  5 , Aaron I Vinik  6 , Carolina M Casellini  6
Affiliations
Review

Diabetic Microvascular Disease: An Endocrine Society Scientific Statement

Eugene J Barrett et al. J Clin Endocrinol Metab. .

Abstract

Both type 1 and type 2 diabetes adversely affect the microvasculature in multiple organs. Our understanding of the genesis of this injury and of potential interventions to prevent, limit, or reverse injury/dysfunction is continuously evolving. This statement reviews biochemical/cellular pathways involved in facilitating and abrogating microvascular injury. The statement summarizes the types of injury/dysfunction that occur in the three classical diabetes microvascular target tissues, the eye, the kidney, and the peripheral nervous system; the statement also reviews information on the effects of diabetes and insulin resistance on the microvasculature of skin, brain, adipose tissue, and cardiac and skeletal muscle. Despite extensive and intensive research, it is disappointing that microvascular complications of diabetes continue to compromise the quantity and quality of life for patients with diabetes. Hopefully, by understanding and building on current research findings, we will discover new approaches for prevention and treatment that will be effective for future generations.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schema of hyperglycemia’s induced pathways to microvascular complications. MAP, mitogen-activated protein.
Figure 2.
Figure 2.
Interplay of hyperglycemia’s toxic mechanisms and tissues’ endogenous protective properties. IGF, insulinlike growth factor.
Figure 3.
Figure 3.
Conceptual diagram showing the effect of hyperglycemia on different mechanisms hypothesized to be involved in the pathogenesis of diabetic retinopathy.
Figure 4.
Figure 4.
Prevalence of any retinopathy and proliferative retinopathy in persons with diabetes by type/onset and duration in the Wisconsin Epidemiologic Study of Diabetic Retinopathy. (A) T1DM diagnosed at age <30 years. (B) T2DM diagnosed at age ≥30 years, taking and not taking insulin.
Figure 5.
Figure 5.
Test of trend P < 0.001 for both groups.
Figure 6.
Figure 6.
Neuroimaging measures related to cerebral small vessel disease and concomitant pathologies.
Figure 7.
Figure 7.
Modified diabetic neuropathy classification first proposed by Thomas. N, normal. Reference: Jirousek et al. (25).
See this image and copyright information in PMC

References

    1. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C; Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. - PubMed
    1. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865. - PubMed
    1. Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Coney J, Orchard TJ, Aiello LP, King GL. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care. 2007;30(8):1995–1997. - PubMed
    1. Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, Strauch CM, Monnier VM, Doria A, Aiello LP, King GL. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care. 2011;34(4):968–974. - PMC - PubMed
    1. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47(6):859–866. - PubMed

Publication types

MeSH terms